PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: New Enterprise Associates, Inc. (NEA)

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Epizyme Closes $40m Series B Financing NEA Joins Syndicate – NEA’s David Mott Joins Board  - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M
Epizyme Closes $40m Series B Financing NEA Joins Syndicate – NEA’s David Mott Joins Board

 

NewswireToday - /newswire/ - Cambridge, MA, United States, 2009/12/08 - Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Financial/Legal/Venture Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Epizyme initially announced a $32M round led by Bay City Capital (BCC) in September of this year. NEA joins an investor group that includes BCC, Amgen Ventures, Astellas Venture, MPM Capital and Kleiner Perkins Caufield and Byers (KPCB). Coincident with the second close of the Series B financing, David M. Mott, NEA General Partner, joins the Company’s Board of Directors.

“Expanding our syndicate to include NEA adds another investor with significant drug‐development and company building expertise as well as substantial capital resources,” said Epizyme CEO Kazumi Shiosaki, PhD. “By raising more capital now, we can continue to aggressively advance our pipeline of histone methyltransferase inhibitors for various oncology indications. I look forward to working with our investors to continue to build a leading company in the promising new area of epigenetics.

Epigenetic enzymes have been identified for their roles in various diseases including cancer, inflammatory conditions, metabolic disorders and neurological and psychiatric diseases. Epizyme is focusing on a specific class of epigenetic enzymes, the histone methyltransferases (HMTs), which represent a novel protein target class that has been associated with a variety of major diseases. In addition to a robust pipeline of novel small‐molecule inhibitors against selected HMTs, Epizyme is developing an integrated platform that allows rapid and efficient identification of potent and selective inhibitorsagainst multiple HMTs and will evaluate these compounds for their potential value across the therapeutic spectrum.

“Epizyme’s founders, management team, collaborators and investors have done an outstanding job of creating a leading company in the rapidly emerging field of epigentic drug development and research,” said Mr. Mott. “Epizyme’s lead programs, as well as its research and development capabilities in the area of histone methyltransferases, promise to create substantial value for both patients and investors. NEA looks forward to working with the Epizyme team and our co‐investors to continue building a great company.”

Mr. Mott focuses on biopharmaceutical investments at NEA. He is Chairman of 3‐V Biosciences and Zyngenia, a Director of Ardelyx and Zosano Pharma, and serves on the advisory board of the Scripps Translational Science Institute. Prior to joining NEA, he was President and CEO of MedImmune, which was acquired by AstraZeneca for $15.6 billion in 2007. During his 16 years at MedImmune, the company grew from a small biotechnology company into one of the five largest biotechnology companies in the world.

About Epizyme
Epizyme, Inc.(epizyme.com), a biopharmaceutical company, was founded in 2007 to create innovative drugs for major diseases based on new discoveries emerging from the field of epigenetcs. Epizyme is initially focusing on histone methyltransferases (HMTs), a large class of epigenetic enzymes that are recognized for the critical roles they play in serious diseases such as cancer. Epizyme is developing an enabling and integrated drug discovery platform that has evolved a robust and sustainable pipeline o first‐in‐class inhibitors of HMTs. Epizyme is located in Cambridge, MA.

Contact: Kazumi Shiosaki, CEO, 617‐500‐7239, kshiosaki[.]epizyme.com.

About New Enterprise Associates (NEA)

New Enterprise Associates, Inc. (nea.com) is a leading venture capital and growth equity firm focused on helping entrepreneurs build transformational businesses across ultiple stages, sectors and geographies. With approximately $11 billion in committed capital, NEA invests in information technology, healthcare and energy technology companies at all stages in a company’s lifecycle, from seed stage through IPO. Since the firm’s founding in 1978, NEA’s experienced management team has invested in over 650 companies, of which more than 165 have gone public and more than 255 have been acquired. In the U.S., NEA has two offices in the Washington, D.C. metropolitan area and one in Menlo Park, California. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Financial/Legal/Venture Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: New Enterprise Associates, Inc. (NEA)

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Financial/Legal/Venture articles,
CATCH Visitors via Your Competitors Announcements!


Epizyme Closes $40m Series B Financing NEA Joins Syndicate – NEA’s David Mott Joins Board

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Press Office - NEA.com 
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any New Enterprise Associates, Inc. (NEA) securities in any jurisdiction including any other companies listed or named in this release.

Financial/Legal/Venture via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From New Enterprise Associates, Inc. (NEA) / Company Profile


Read Financial/Legal/Venture Most Recent Related Newswires:

Infinera to Participate in Upcoming Investor Conference
Propel Financial Services Partners with Clear Payment Solutions
Digital Payments Power Growth in Booming Asia-Pacific Financial Technology Landscape Notes Frost & Sullivan
Digital Readiness Key to Growth Opportunities in the Financial Services Market
Prairie Capital Advisors Announces The Sale of Cornerstone Treatment Facilities Network to An ESOP
Koch Agrees to Invest Over $2 Billion in Infor
FTI Consulting Recognized as a Top Service Provider in the Legal Industry
GE Completes Spin Off and Demerger of Bank BPH Core Bank to Alior Bank
ALM Expands Senior Leadership Team, Organization Focused on Customers and Transformation
Lazard Acquires Remaining 50% Stake in MBA Lazard - Fully Integrating its Latin American Operations
Western Union Business Solutions Announce Mark Davis As Head of Australia and New Zealand
Tabarak Investment Capital and Elite Capital & Co. Limited in Discussion to Finance Projects
Consulting Magazine Unveils the Profession’s Fastest Growing Firms At Inaugural Gala
Hills Invest Signs An Agreement with The Afore Profuturo in Mexico
TRA Searches for TPA Acquisition Opportunities

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)